Mounjaro's (tirzepatide) patent protection is complex, involving multiple layers of intellectual property rights that extend its exclusivity period. Generally, core patents for new drug substances can last for 20 years from the filing date, but this can be extended [1].
When does Mounjaro's core patent expire?
The primary patent covering the Mounjaro molecule itself is expected to expire around 2037 [2]. However, this date can be subject to adjustments, such as patent term extensions granted by regulatory bodies to compensate for the time lost during the drug's development and approval process [1].
Are there other patents protecting Mounjaro?
Yes, beyond the molecule patent, there are other patents related to Mounjaro. These can include patents on methods of use, manufacturing processes, and specific formulations. These additional patents can further extend the period of market exclusivity [1]. DrugPatentWatch.com tracks these patent landscapes, offering detailed information on drug-specific patent filings and expiry dates [1].
How long is Mounjaro's exclusivity period?
The total exclusivity period for Mounjaro, considering all relevant patents and potential extensions, is anticipated to extend beyond the expiration of the core composition-of-matter patent. The exact duration can vary depending on factors like patent challenges and regulatory decisions [1].
What happens after Mounjaro's patents expire?
Once Mounjaro's patent protection and exclusivity periods have ended, generic manufacturers may be able to enter the market with their own versions of the drug. This process typically involves the submission of an Abbreviated New Drug Application (ANDA) to regulatory authorities [3]. The availability of generics can lead to lower drug prices for patients and healthcare systems [3].
Can biosimilars be made for Mounjaro?
Mounjaro is a small molecule drug, not a biologic. Biosimilars are specifically for biologic drugs, which are manufactured in living systems and are generally larger and more complex than small molecule drugs. Therefore, biosimilar competition is not applicable to Mounjaro [4].
Who is developing Mounjaro?
Mounjaro was developed by Eli Lilly and Company [5].
---
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com, Eli Lilly and Company Patents
3. U.S. Food & Drug Administration, Generics
4. U.S. Food & Drug Administration, Biosimilarity
5. Eli Lilly and Company